UK biopharmaceuticals research projects win £4m of funding
Aim to strengthen UK’s position in the sector
These projects will provide the foundations for the UK pharmaceutical sector to strengthen its position in the biopharmaceutical sector to the benefit of society and the economy.
The Bioprocessing Research Industry Club (BRIC), a Biotechnology and Biological Sciences Research Council (BBSRC)-led public-private partnership with the Engineering and Physical Sciences Research Council (EPSRC) and a consortium of 16 industrial partners, including companies such as Pfizer, GlaxoSmithKline, Lonza and Biodesign, is providing £4m to fund the projects.
This money will go to six research projects, eight PhD studentships and a Skills Development School for early stage researchers.
The projects will address current challenges in bioprocessing, while the PhD studentships and Skills Development School will ensure that the next generation of researchers have the technical knowledge and personal skills to secure future UK success in producing biopharmaceuticals.
Each PhD student will spend six months or a year on placement with a partner company where they will develop an understanding of the challenges involved in producing biological medicines on a commercial scale.
Biopharmaceuticals such as vaccines, monoclonal antibodies, hormones and peptide therapeutics, make up over a third of the medicines currently under development and the number of licensed biological medicines is expected to grow by 20% a year.
You may also like
Research & Development
COVID-19 immunity lowers the risk of a new pandemic
Researchers at the MRC-University of Glasgow Centre for Virus Research have demonstrated that the likelihood of the emergence of a new SARS-type virus pandemic has been significantly reduced by population-wide immunity to SARS-CoV-2
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Cytiva enters research partnership with SRTIGET for next-gen genomic medicine
The pair aim to expand the role of lipid nanoparticle technology into gene therapy delivery, including applications in cancer and inherited blood diseases, CNS delivery for neurological disorders where current methods fail and in vivo stem cell modification that could eliminate toxic conditioning regimens
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Finance
Investing in the future of healthcare: from diagnostics innovation to scientific talent pipelines
Strategic UK investment in next-generation cancer diagnostics and cardiovascular research training is accelerating innovation, reducing barriers to adoption and building the multidisciplinary talent needed to deliver long-term improvements in patient outcomes and life sciences growth
Research & Development
Just – Evotec Biologics wins BARDA contract to optimise antibody biomanufacturing against Ebola and Sudan virus
Just – Evotec Biologics has been selected by BARDA to develop scalable, high-yield manufacturing processes for a monoclonal antibody cocktail targeting filovirus diseases under a multi-year programme valued at up to $10m